News

Prime Therapeutics has studied the costs and clinical events relationship among their members using a controlled substances (CS) score algorithm that identifies potential overuse/abuse of opioids/controlled substances.

We want to know what you think about the top policy issues facing the industry. Please take our quick survey. You’ll be entered to win a $200 Visa gift card.

One month into 2016, it’s clear that this will be a year of massive change for the managed care industry. Here are seven predictions for some of the key issues that will emerge, intensify, or be resolved by the end of this year.

When the House Committee on Oversight and Government Reform met on January 26, legislators took a closer look at price hikes from companies such as Valeant Pharmaceuticals and Turing Pharmaceuticals.

Eli Lilly & Company finally releases a high-dose insulin pen, which will help cut down on medication errors associated with the U-100 Humulin insulin pens.

To help ensure you are doing all you can to prevent a security breach, we asked the experts to weigh in. Here they identify four of the biggest mistakes health plans are making.

Abbott's Compounding Pharmacy in Berkeley, Calif., is voluntarily recalling all unexpired lots of sterile compounded products because of lack of sterility assurance.

There is some good news for heart failure patients’ life expectancy, in a recent study published in the New England Journal of Medicine.

FDA advisers recommended approval of the first long-acting, subdermal buprenorphine implant (Probuphine, Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals) for the maintenance treatment of opioid addiction.